Format

Send to

Choose Destination
Lancet Neurol. 2018 Nov;17(11):994-1005. doi: 10.1016/S1474-4422(18)30311-9. Epub 2018 Sep 21.

Comorbidities, treatment, and pathophysiology in restless legs syndrome.

Author information

1
Department of Neurosurgery, University Medical Center, Goettingen, Germany; Paracelsus-Elena Hospital, Kassel, Germany. Electronic address: claudia.trenkwalder@med.uni-goettingen.de.
2
Sleep Disorders Center, Johns Hopkins Bayview Medical Center, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.
3
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
4
Department of Physiology, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
5
Department of Neurosurgery, Penn State Hershey Medical Center, Hershey, PA, USA.
6
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
7
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany; Institute of Human Genetics, Technical University, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

Abstract

Restless legs syndrome, also known as Willis-Ekbom disease, is a common neurological condition whose manifestation is affected by complex environmental and genetic interactions. Restless legs syndrome can occur on its own, mostly at a young age, or with comorbidities such as cardiovascular disease, diabetes, and arterial hypertension, making it a difficult condition to properly diagnose. However, the concept of restless legs syndrome as being two entities, primary or secondary to another condition, has been challenged with genetic data providing further insight into the pathophysiology of the condition. Although dopaminergic treatment was formerly the first-line therapy, prolonged use can result in a serious worsening of symptoms known as augmentation. Clinical studies on pregabalin, gabapentin enacarbil, oxycodone-naloxone, and iron preparations have provided new treatment options, but most patients still report inadequate long-term management of symptoms. Studies of the hypoxic pathway activation and iron deficiency have provided valuable information about the pathophysiology of restless legs syndrome that should now be translated into new, more effective treatments for restless legs syndrome.

PMID:
30244828
DOI:
10.1016/S1474-4422(18)30311-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center